We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 91.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
101
Exelixis
EXEL
$13.9B
– –
-513,410
Closed -$11M
CBIO
102
Crescent Biopharma
CBIO
$546M
– –
-2,912
Closed -$4.7M
MDWD icon
103
MediWound
MDWD
$184M
– –
-32,286
Closed -$1.56M
MGNX icon
104
MacroGenics
MGNX
$233M
– –
-217,695
Closed -$4.5M
NTRA icon
105
Natera
NTRA
$36.4B
– –
-228,676
Closed -$4.3M
RIGL icon
106
Rigel Pharmaceuticals
RIGL
$723M
– –
-104,161
Closed -$2.95M
RNAC icon
107
Cartesian Therapeutics
RNAC
$218M
– –
-3,125
Closed -$1.24M
TNXP icon
108
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– -$3.11M
VNDA icon
109
Vanda Pharmaceuticals
VNDA
$304M
– –
-310,354
Closed -$5.91M
LUMO
110
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-56,364
Closed -$2.42M
TRVN
111
DELISTED
Trevena, Inc.
TRVN
– –
-1,520
Closed -$1.37M
TTOO
112
DELISTED
T2 Biosystems, Inc
TTOO
– –
-20
Closed -$774K
ACOR
113
DELISTED
Acorda Therapeutics
ACOR
– –
-1,443
Closed -$4.97M
JNCE
114
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-100,000
Closed -$766K
AERI
115
DELISTED
Aerie Pharmaceuticals
AERI
– –
-60,155
Closed -$4.06M
NBRV
116
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-3,753
Closed -$3.27M
TTPH
117
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-46,750
Closed -$3.34M
PGNX
118
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-979,016
Closed -$7.87M
STML
119
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-44,524
Closed -$715K
BTX.WS
120
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
– –
-20,084
Closed -$1K
BDSI
121
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-210,021
Closed -$620K
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Baker Bros. Advisors held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Baker Bros. Advisors's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Baker Bros. Advisors fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Baker Bros. Advisors opened 12 new positions and closed 27 in Q3 2018.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.